Harel Insurance Investments & Financial Services Ltd. lowered its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 28.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,748 shares of the biotechnology company’s stock after selling 16,380 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Exelixis were worth $1,791,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also modified their holdings of EXEL. Motiv8 Investments LLC acquired a new position in Exelixis in the fourth quarter valued at $26,000. Acumen Wealth Advisors LLC acquired a new stake in shares of Exelixis in the fourth quarter valued at approximately $29,000. Activest Wealth Management acquired a new stake in Exelixis during the 4th quarter worth $32,000. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Exelixis by 1,380.4% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock worth $34,000 after buying an additional 773 shares during the last quarter. Finally, V Square Quantitative Management LLC acquired a new position in shares of Exelixis in the fourth quarter valued at approximately $44,000. Institutional investors and hedge funds own 85.27% of the company’s stock.
Exelixis Stock Down 0.4%
EXEL opened at $55.55 on Thursday. Exelixis, Inc. has a 52-week low of $33.76 and a 52-week high of $57.57. The firm has a market capitalization of $13.96 billion, a P/E ratio of 18.46, a P/E/G ratio of 1.61 and a beta of 0.42. The firm’s 50 day moving average is $52.30 and its 200-day moving average is $46.66.
Analysts Set New Price Targets
EXEL has been the subject of a number of recent analyst reports. Morgan Stanley restated a “positive” rating on shares of Exelixis in a research report on Monday, June 22nd. Citizens Jmp lifted their target price on shares of Exelixis from $50.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Wednesday, June 24th. HC Wainwright reiterated a “buy” rating and set a $56.00 price objective on shares of Exelixis in a research report on Thursday, July 2nd. Royal Bank Of Canada increased their price target on Exelixis from $43.00 to $46.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings raised shares of Exelixis from a “buy (b)” rating to a “buy (b+)” rating in a research report on Wednesday, July 8th. Nine investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $48.80.
Read Our Latest Stock Analysis on EXEL
Insider Transactions at Exelixis
In other news, CFO Christopher J. Senner sold 34,901 shares of Exelixis stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the completion of the transaction, the chief financial officer directly owned 952,317 shares of the company’s stock, valued at approximately $47,615,850. The trade was a 3.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jack L. Wyszomierski sold 3,925 shares of Exelixis stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $50.55, for a total value of $198,408.75. Following the completion of the transaction, the director owned 284,384 shares of the company’s stock, valued at approximately $14,375,611.20. The trade was a 1.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 219,170 shares of company stock valued at $10,620,641 over the last 90 days. Corporate insiders own 2.60% of the company’s stock.
Exelixis Profile
Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
Read More
- Five stocks we like better than Exelixis
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
